Why Hong Kong's New Drug Regulator Must Earn Global Trust Before Anything Else

Why Hong Kong's New Drug Regulator Must Earn Global Trust Before Anything Else

For decades, Hong Kong didn't actually approve new drugs on its own. It relied on a "secondary evaluation" system, waiting for agencies like the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) to do the heavy lifting first. That era ends right now. With the Hong Kong Centre for Medical Products Regulation (CMPR) launching at the end of 2026, the city is stepping into the high-stakes business of independent drug evaluation.

Leading this massive shift is Li Zili, who took office on October 20, 2026, as the Controller for Medical Products Regulation. His mandate sounds straightforward on paper: build international trust and accelerate medical innovation. In practice, those two goals constantly pull against each other. Move too slowly, and biotech firms take their clinical trials elsewhere. Move too fast without ironclad scientific rigor, and global regulators will ignore Hong Kong's stamp of approval.

Who Is Li Zili and Why His Resume Matters

You don't build a brand-new regulatory authority from scratch with a career bureaucrat who has never reviewed a clinical trial dossier. When the Hong Kong government conducted its global open recruitment exercise, they specifically hunted for someone who understood both Western regulatory science and Chinese pharmaceutical development.

Li Zili brings over 30 years of experience across both sides of that divide. Before taking the helm in Hong Kong, he worked inside the US FDA and served as Head of Asia-Pacific R&D at Johnson & Johnson. He also played a direct role in helping China's former drug regulator (CFDA, now the NMPA) join the International Council for Harmonisation (ICH) back in 2017.

That specific combination isn't accidental. Director of Health Dr. Ronald Lam noted when announcing the appointment that Li possesses practical regulatory affairs experience alongside deep familiarity with international medical product policies. More importantly, biotech executives in Boston, Basel, and Shanghai already know who he is. When a new agency asks multinational drugmakers to submit raw pre-clinical and clinical trial data for a primary review, personal credibility at the top buys you a seat at the table.

The Real Meaning Behind Hong Kong Joining the ICH

Timing matters in regulatory strategy. Just weeks after Li took office, Hong Kong formally became a regulatory member of the International Council for Harmonisation (ICH) on November 20, 2026.

Many casual observers miss why this is such a big deal. Here is what ICH regulatory membership actually changes on the ground:

  • Global Rulebook Alignment: Hong Kong now operates under the exact same technical guidelines for drug safety, efficacy, and quality as the US FDA, the European Union, Switzerland, Japan, and mainland China.
  • From Follower to Rule-Maker: Previously, Hong Kong simply adopted standards written by others. As Dr. Ronald Lam pointed out, the CMPR can now send its own experts to help draft and revise international ICH guidelines.
  • Speed of Execution: Secretary for Health Prof. Lo Chung-mau highlighted that Hong Kong went from an ICH observer in October 2023 to a full regulatory member in just three years—far faster than the eight to ten years international benchmarks usually require.

Combined with Hong Kong's existing membership in the Pharmaceutical Inspection Co-operation Scheme (PIC/S) since 2016, the city now holds the two primary international credentials required to be taken seriously as a standalone medicines authority.

How Primary Evaluation Actually Works in Practice

If you work in regulatory affairs or biotech venture capital, you've probably heard plenty of buzzwords about Hong Kong becoming a "health and medical innovation hub." Strip away the policy speeches, and the core mechanism is primary evaluation.

Under the old rules, if a biotech startup developed a breakthrough oncology drug in Shenzhen or Hong Kong, it couldn't get primary approval in Hong Kong first. It had to get approved in two reference countries (like the US and UK) before Hong Kong would verify it. That forced innovative Chinese therapies to seek Western approvals first just to come back home.

The new system flips that workflow, though it isn't happening overnight. Hong Kong is rolling out primary evaluation across four distinct phases, aiming for full coverage of all pharmaceutical products by 2030:

  1. Phase 1 (Launched in 2026): Covers New Drug Applications (NDA-2 and NDA-3) for chemical entities—essentially new formulations, new routes of administration, or quality and manufacturing extensions. Companies must complete a mandatory pre-NDA meeting with regulators before filing.
  2. Phase 2: Expands primary evaluation to registered biological entities with extended applications.
  3. Phases 3 and 4: Gradually brings brand-new chemical entities (NCEs) and novel biologics under full primary review, reviewing raw animal testing, human clinical data, and pharmacovigilance plans directly.

Alongside primary evaluation, Hong Kong is maintaining its "abridged evaluation" pathway for therapies addressing urgent unmet local medical needs or drugs holding breakthrough designations in reference markets that have supporting Asian clinical data.

The Bottlenecks Nobody Likes to Talk About

Pledging to build trust is easy during a press conference. Executing primary drug reviews day after day is brutally hard, and Hong Kong faces three real structural hurdles that Li Zili will have to solve during his three-year term.

The Talent Shortage Is Real

Reviewing a primary New Drug Application requires dozens of specialized toxicologists, clinical pharmacologists, biostatisticians, and Good Manufacturing Practice (GMP) inspectors. Hong Kong has world-class medical schools at HKU and CUHK, yet its local pool of experienced regulatory reviewers is tiny. Building a team capable of scrutinizing complex cell and gene therapies without creating a two-year review backlog will require aggressive international recruiting and tight collaboration with mainland and overseas experts.

Market Size vs. Regulatory Effort

Let's be honest about the commercial math. Hong Kong has roughly 7.5 million people. For a global pharmaceutical company, filing a primary dossier—which costs millions of dollars in regulatory preparation—just to access 7.5 million patients makes zero financial sense on its own.

Hong Kong's approval only becomes commercially irresistible if it acts as a springboard into the Greater Bay Area (86 million people) and broader Asian markets. Right now, mainland China's "Hong Kong and Macao Medicine and Equipment Connect" policy already allows certain Hong Kong-registered drugs and devices to be used in designated Greater Bay Area hospitals. If the CMPR can turn a Hong Kong primary approval into a recognized fast-track credential across Southeast Asia and mainland China, biotechs will line up at the door. If not, firms will stick to filing with the FDA and NMPA first.

Geopolitical Friction

Operating under the "one country, two systems" framework gives Hong Kong a unique position as a bridge between Chinese biotech innovation and global capital. In 2026, Chinese biotechs have generated tens of billions of dollars in out-licensing deals, proving their science is globally competitive. Yet geopolitical tensions between Washington and Beijing still complicate cross-border clinical trials and data sharing.

To maintain international trust, the CMPR has to prove beyond any doubt that its scientific decisions are strictly independent, transparent, and immune to political or commercial pressure. Even one high-profile approval of a drug with weak clinical efficacy data would set the agency's international reputation back by a decade.

What Biotech Leaders and Investors Should Do Next

If you're managing regulatory strategy, clinical development, or biotech investments in Asia, you shouldn't sit on the sidelines waiting until 2030. The transition is already reshaping how clinical trials are designed in the Pearl River Delta.

Start by auditing your current pipeline against the CMPR's phased rollout. If you have chemical entity line extensions or reformulations (NDA-2 or NDA-3), engage with the Preparatory Office and Drug Office early to schedule a pre-NDA consultation. Regulators in a newly formed agency are usually far more accessible and collaborative during their first year of operations than established bureaucracies are.

Second, design your early-phase clinical trials in Hong Kong and the Greater Bay Area to meet full ICH Good Clinical Practice (GCP) standards from day one. With Hong Kong establishing its International Clinical Trial Academy and Real-World Study and Application Centre, data generated locally is now built to travel across borders. Make sure your trial endpoints and Asian subgroup data satisfy both CMPR reviewers and Western authorities simultaneously so you never have to run the same study twice.

KF

Kenji Flores

Kenji Flores has built a reputation for clear, engaging writing that transforms complex subjects into stories readers can connect with and understand.